Natera Competitive Intelligence & Landscape

Natera offers a comprehensive portfolio of genetic tests. In oncology, key products include Signatera™ for residual disease (MRD) testing, Latitude™ for tissue-free MRD, Altera™ for tumor genomic profiling, and Empower™ for hereditary cancer. For organ health, they provide Prospera™ for transplant assessment (kidney, heart, lung) and Renasight™ for kidney gene panels. Their women's health offerings feature Horizon™ for advanced carrier screening, Panorama™ for noninvasive prenatal testing (NIPT), Vistara™ for single-gene NIPT, and Anora™ for miscarriage testing. They also offer Zenith™ for rare disease genomics.

Natera primarily targets patients, clinicians, and biopharma partners, providing various services such as genetic information sessions, test kit orders, and EHR integration. The company has a significant presence in the genetic testing market, with their Panorama™ test being recognized as the most accurate non-invasive prenatal test. The company also provides support through resources like the NateraConnect Provider Portal and the Natera Patient Assistant.

Headquartered in San Carlos, CA, with an additional office in Austin, TX, Natera is powered by a team of over 3,000

For Women's Health tests like Panorama™, Horizon™, Empower™, and Vistara™, Natera offers a dedicated form to request a cost estimate, with a support team contacting individuals within several days of submission [natera.com/womens-health/pricing-billing/cost-estimate/]. The cost of Panorama™, a highly accurate prenatal screening test, varies, and Natera aims for transparency in billing for all its services [natera.com/womens-health/panorama-nipt-prenatal-screening/faq/].

In Organ Health, tests such as Prospera™ for transplant assessment and Renasight™ for kidney gene panels are covered by Medicare for select indications [natera.com/organ-health/prospera-organ-transplantation-assessment/faq/].

Natera welcomes all insurance plans, including Medicare, and provides prompt-pay cash prices and financial assistance options. Billing support is available via phone for any inquiries [natera.com/organ-health/organ-health-pricing-billing/].

For Oncology tests, including Signatera™ for residual disease and Altera™ for tumor genomic profiling, Natera also accepts self-pay pricing and offers financial assistance.

Signatera™, a personalized cancer management test, is covered by Medicare for specific indications [natera.com/oncology/signatera-advanced-cancer-detection/]. Billing support for oncology services is available by phone during business hours [natera.com/oncology/billing/].

While Natera's main careers page invites prospective employees to view job openings and learn about benefits, an investor-focused careers page indicates there may not always be opportunities available, suggesting that hiring can be targeted rather than continuous across all departments. Despite this, the company's overall trajectory reflects a growing workforce, with Natera reporting 4.3K employees and a 28% year-over-year increase, indicating a positive hiring trend.

This expansion and consistent growth in employee numbers align with Natera's mission to integrate personalized genetic testing into standard healthcare practices. The focus on new roles in laboratory and operational functions, as well as professional positions, underscores Natera's dedication to enhancing its research, development, and delivery of advanced diagnostic solutions. The company's recognition on U.S. News & World Report's 2024 "Best Companies to Work For in Healthcare" ranking further highlights its commitment to attracting and retaining talent, supporting its strategic objectives in a competitive industry.

The company's growth trajectory continued into 2026, with first-quarter revenues reaching $696.6 million, an increase of 38.8% compared to $501.8 million in the first quarter of 2025 [source]. Similarly, the fourth quarter of 2025 generated $665.5 million in total revenues, a 39.8% increase from $476.1 million in the fourth quarter of 2024 [source].

Natera also reported strong performance in the second quarter of 2025, with total revenues of $546.6 million, up 32.2% from $413.4 million in the second quarter of 2024 [source]. The company has consistently achieved positive cash inflow and maintained strong gross margins, indicating solid financial health. In the first quarter of 2026, Natera achieved a gross margin of 64.2%, up from 63.1% in the first quarter of 2025 [source].

The company is a regular presence at significant healthcare conferences. For instance, Natera announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, held on January 13, 2026, where management delivered a presentation [https://www.natera.com/company/news/natera-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference/][https://investor.natera.com/events-and-presentations/events/event-details/2026/44th-Annual-JP-Morgan-Healthcare-Conference-2026-8khCChg0K_/default.aspx]. They also plan to attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 [https://investor.natera.com/events-and-presentations/events/default.aspx].

Natera frequently presents new research and data at major medical meetings. They announced a landmark oncology data program for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 29–June 2, where they planned to present 35 studies [https://www.natera.com/company/news/natera-to-present-35-studies-at-asco-extending-clinical-data-leadership-in-oncology/].

In addition to in-person conferences, Natera hosts and participates in webinars to disseminate information. Examples include a webinar on March 17, 2026, discussing new EXPAND & VANISH data presented at SMFM 2026 [https://info.natera.com/EXPAND-and-SMFM-Recap-Reg-Page]. Another webinar series, "Driving Precision in Breast Cancer Care," included a session on October 16, 2025, focused on optimizing breast cancer surveillance with MRD testing [https://info.natera.com/Breast-Cancer-Surveillance-Registration-Page]. The company also conducts quarterly earnings conference calls, such as the Q1 Earnings Conference Call on May 7, 2026, and the Q4 Earnings Conference Call on February 26, 2026 [https://investor.natera.com/events-and-presentations/events/default.aspx][https://investor.natera.com/events-and-presentations/events/event-details/2026/Natera-Inc-Q4-Earnings-Conference-Call/default.aspx].